<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37043475</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Genetic variability in sporadic amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>3760</StartPage><EndPage>3769</EndPage><MedlinePgn>3760-3769</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awad120</ELocationID><Abstract><AbstractText>With the advent of gene therapies for amyotrophic lateral sclerosis (ALS), there is a surge in gene testing for this disease. Although there is ample experience with gene testing for C9orf72, SOD1, FUS and TARDBP in familial ALS, large studies exploring genetic variation in all ALS-associated genes in sporadic ALS (sALS) are still scarce. Gene testing in a diagnostic setting is challenging, given the complex genetic architecture of sALS, for which there are genetic variants with large and small effect sizes. Guidelines for the interpretation of genetic variants in gene panels and for counselling of patients are lacking. We aimed to provide a thorough characterization of genetic variability in ALS genes by applying the American College of Medical Genetics and Genomics (ACMG) criteria on whole genome sequencing data from a large cohort of 6013 sporadic ALS patients and 2411 matched controls from Project MinE. We studied genetic variation in 90 ALS-associated genes and applied customized ACMG-criteria to identify pathogenic and likely pathogenic variants. Variants of unknown significance were collected as well. In addition, we determined the length of repeat expansions in C9orf72, ATXN1, ATXN2 and NIPA1 using the ExpansionHunter tool. We found C9orf72 repeat expansions in 5.21% of sALS patients. In 50 ALS-associated genes, we did not identify any pathogenic or likely pathogenic variants. In 5.89%, a pathogenic or likely pathogenic variant was found, most commonly in SOD1, TARDBP, FUS, NEK1, OPTN or TBK1. Significantly more cases carried at least one pathogenic or likely pathogenic variant compared to controls (odds ratio 1.75; P-value 1.64 &#xd7; 10-5). Isolated risk factors in ATXN1, ATXN2, NIPA1 and/or UNC13A were detected in 17.33% of cases. In 71.83%, we did not find any genetic clues. A combination of variants was found in 2.88%. This study provides an inventory of pathogenic and likely pathogenic genetic variation in a large cohort of sALS patients. Overall, we identified pathogenic and likely pathogenic variants in 11.13% of ALS patients in 38 known ALS genes. In line with the oligogenic hypothesis, we found significantly more combinations of variants in cases compared to controls. Many variants of unknown significance may contribute to ALS risk, but diagnostic algorithms to reliably identify and weigh them are lacking. This work can serve as a resource for counselling and for the assembly of gene panels for ALS. Further characterization of the genetic architecture of sALS is necessary given the growing interest in gene testing in ALS.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Daele</LastName><ForeName>Sien Hilde</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-3005-3619</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, and Leuven Institute for Neuroscience and Disease (LIND), 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human genetics, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moisse</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, and Leuven Institute for Neuroscience and Disease (LIND), 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vugt</LastName><ForeName>Joke J F A</ForeName><Initials>JJFA</Initials><Identifier Source="ORCID">0000-0002-4161-4004</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwamborn</LastName><ForeName>Ramona A J</ForeName><Initials>RAJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Spek</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rheenen</LastName><ForeName>Wouter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Eijk</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenna</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre SLA, CHRU de Tours, 37044 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253, iBrain, Universit&#xe9; de Tours, Inserm, 37032 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, Universit&#xe9; de Tours, Inserm, 37032 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre SLA, CHU Limoges, 87042 Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin D02 PN40, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughin</LastName><ForeName>Russell</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3915-2135</Identifier><AffiliationInfo><Affiliation>Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin D02 PN40, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, 91120 Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drory</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tel-Aviv Sourasky Medical Centre, 64239 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5963-7426</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, 20149 Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Universit&#xe0; degli Studi di Milano, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7698-3854</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, 20149 Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Universit&#xe0; degli Studi di Milano, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratti</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, 20149 Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, Universit&#xe0; degli Studi di Milano, 20133 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora Pardina</LastName><ForeName>Jes&#xfa;s S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>ALS Unit, Hospital University San Rafael, 28016 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servei de Neurologia, HUB-IDIBELL, 08908 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, 901 87 Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba&#x15f;ak</LastName><ForeName>Nazli A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Ko&#xe7; University, School of Medicine, KUTTAM-NDAL, 34010 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, King's College London, Department of Basic and Clinical Neuroscience, London SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8925-2567</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast BT9 7BL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-7709-5883</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, King's College London, Department of Basic and Clinical Neuroscience, London SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, and Leuven Institute for Neuroscience and Disease (LIND), 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NIHR202421</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">complex genetic disease</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">oligogenic inheritance</Keyword></KeywordList><CoiStatement>J.V. reports to have sponsored research agreements with Biogen and Astra Zeneca. A.A.-C reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, Sano, Sanofi and Wave Pharmaceuticals. P.V.D. has served in advisory boards for Biogen, CSL Behring, Alexion Pharmaceuticals, Ferrer, QurAlis, Cytokinetics, Argenx, UCB, Muna Therapeutics, Alector, Augustine Therapeutics, VectorY and Zambon.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>13</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37043475</ArticleId><ArticleId IdType="pmc">PMC10473563</ArticleId><ArticleId IdType="doi">10.1093/brain/awad120</ArticleId><ArticleId IdType="pii">7116215</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085.</Citation><ArticleIdList><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk AE, Weishaupt JH, Andersen PM, Ludolph AC, Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018;30:252&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Heverin M, Elamin M, et al. . Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol. 2013;74:699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">23836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech. 2017;10:537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, et al. . An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81:1324&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Leblond CS, Kaneb HM, Dion PA, Rouleau GA. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol. 2014;262(Pt B):91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">24780888</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, van Es MA, Hennekam EAM, et al. . Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:3776&#x2013;3784.</Citation><ArticleIdList><ArticleId IdType="pubmed">22645277</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Mangelsdorf M, Fan D, Bartlett P, Brown MA. Amyotrophic lateral sclerosis genetic studies: from genome-wide association mapping to genome sequencing. Neuroscientist. 2015;21:599&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">25378359</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston CA, Stanton BR, Turner MR, et al. . Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219036</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S, Shatunov A, Sproviero W, et al. . A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140:1611&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5445258</ArticleId><ArticleId IdType="pubmed">28430856</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller K, Brenner D, Weydt P, et al. . Comprehensive analysis of the mutation spectrum in 301 German ALS families. Journal of neurology. Neurosurgery &amp; Psychiatry. 2018;89:817&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">29650794</ArticleId></ArticleIdList></Reference><Reference><Citation>Debray S, Race V, Crabb&#xe9; V, et al. . Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. Neurobiol Aging. 2013;34:2890.e7&#x2013;e2890.e12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23870417</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J, Raphael AR, Daneshjou R, Gitler AD. Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis. PLoS Genet. 2014;10:e1004704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191946</ArticleId><ArticleId IdType="pubmed">25299611</ArticleId></ArticleIdList></Reference><Reference><Citation>Project Mine ALS Sequencing Consortium . Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum Genet. 2018;26:1537&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al. . Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015; 17:405&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisse M, Zwamborn RAJ, van Vugt J, et al. . The effect of SMN gene dosage on ALS risk and disease severity. Ann Neurol. 2021;89:686&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048961</ArticleId><ArticleId IdType="pubmed">33389754</ArticleId></ArticleIdList></Reference><Reference><Citation>
Online Mendelian Inheritance in Man, OMIM&#xae;. Accessed 28 April
2021. https://omim.org/</Citation></Reference><Reference><Citation>
Neuromuscular Disease Centre . Accessed 28 April 2021. https://neuromuscular.wustl.edu/</Citation></Reference><Reference><Citation>Benarroch L, Bonne G, Rivier F, Hamroun D. The 2021 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2020; 30:1008&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257164</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSod: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012;33:1345&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>
GTEx Portal.
Accessed 25 November 2021. https://gtexportal.org/home/</Citation></Reference><Reference><Citation>Yates AD, Achuthan P, Akanni W, et al. . Ensembl 2020. Nucleic Acids Res. 2020;48(D1):D682&#x2013;D688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145704</ArticleId><ArticleId IdType="pubmed">31691826</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolzhenko E, Deshpande V, Schlesinger F, et al. . Expansionhunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics. 2019;35:4754&#x2013;4756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853681</ArticleId><ArticleId IdType="pubmed">31134279</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CGJ, et al. . Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott AD, Huang KL, Weerasinghe A, et al. . Charger: clinical characterization of germline variants. Bioinformatics. 2019;35:865&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394391</ArticleId><ArticleId IdType="pubmed">30102335</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Lee JM, Benson M, et al. . Clinvar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062&#x2013;D1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753237</ArticleId><ArticleId IdType="pubmed">29165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou J, Zhu LJ. Trackviewer: A bioconductor package for interactive and integrative visualization of multi-omics data. Nat Methods. 2019;16:453&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">31133757</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Allred P, Bali T, et al. . Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015;77:100&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293318</ArticleId><ArticleId IdType="pubmed">25382069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7:710&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay C, Collins JA, Miedzybrodzka Z, et al. . Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2016;87:282&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4955276</ArticleId><ArticleId IdType="pubmed">27335115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardiner SL, Boogaard MW, Trompet S, et al. . Prevalence of carriers of intermediate and pathological polyglutamine disease-associated alleles among large population-based cohorts. JAMA Neurol. 2019;76:650&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563569</ArticleId><ArticleId IdType="pubmed">30933216</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Marangi G, Doronzio PN, et al. . High-Throughput genetic testing in ALS: the challenging path of variant classification considering the ACMG guidelines. Genes (Basel). 2020;11:1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7600768</ArticleId><ArticleId IdType="pubmed">32987860</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wang K. Intervar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet. 2017;100:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5294755</ArticleId><ArticleId IdType="pubmed">28132688</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Bede P, Elamin M, et al. . Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:157&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>